Edition:
United Kingdom

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

19.00USD
17 Aug 2018
Change (% chg)

$0.25 (+1.33%)
Prev Close
$18.75
Open
$18.80
Day's High
$19.05
Day's Low
$18.50
Volume
84,049
Avg. Vol
153,853
52-wk High
$19.60
52-wk Low
$8.07

Latest Key Developments (Source: Significant Developments)

Coherus Biosciences Q2 Loss Per Share $0.68
Wednesday, 8 Aug 2018 

Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.68.Q2 EARNINGS PER SHARE VIEW $-0.64 -- THOMSON REUTERS I/B/E/S.SEES CASH USE IN OPERATIONS OF ABOUT $48 TO $53 MILLION FOR Q3.COHERUS BIOSCIENCES - CASH AND CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES TOTALED $159.8 MILLION AT QUARTER-END VERSUS $95.2 MILLION AS OF MARCH 31.  Full Article

Coherus Biosciences Receives Positive CHMP Opinion For UDENYCA™ (Pegfilgrastim Biosimilar Candidate)
Friday, 27 Jul 2018 

July 27 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES RECEIVES POSITIVE CHMP OPINION FOR UDENYCA™ (PEGFILGRASTIM BIOSIMILAR CANDIDATE).COHERUS BIOSCIENCES - EUROPEAN COMMISSION DECISION ON APPROVAL FOR UDENYCA IS EXPECTED IN OCTOBER.  Full Article

Coherus Says Subsequent To CHMP Meet Of June 27 To Consider Chs-1701 Application
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Coherus BioSciences Inc ::COHERUS- SUBSEQUENT TO CHMP MEET OF JUNE 27 TO CONSIDER CHS-1701 APPLICATION, CHMP IDENTIFIED SOME OUTSTANDING ISSUES ARISING FROM DAY 180 RESPONSES.COHERUS BIOSCIENCES SAYS SUBMITTED A FULL RESPONSE TO CHMP ISSUES ON JULY 3 2018 - SEC FILING.COHERUS BIOSCIENCES-NOW GOT WRITTEN (CO)-RAPPORTEURS JOINT ASSESSMENT REPORT STATING CONCLUSION THAT OUTSTANDING ISSUES WERE SATISFACTORILY ADDRESSED.COHERUS BIOSCIENCES INC - EXPECTS CHS-1701 APPLICATION WILL BE INCLUDED ON AGENDA FOR JULY 2018 CHMP MEETING.COHERUS BIOSCIENCES INC - UNDERSTANDS THAT JOINT ASSESSMENT REPORT IS NOW UNDER REVIEW BY CHMP.COHERUS BIOSCIENCES - NOW GOT WRITTEN (CO)-RAPPORTEURS JOINT ASSESSMENT REPORT STATING CONCLUSION NO FURTHER CONCERNS REMAIN RELATED TO CHS-1701 APPLICATION.  Full Article

Coherus Biosciences Says CHMP Requires Further Interactions With Co Regarding It's Pegfilgrastim Biosimilar
Monday, 25 Jun 2018 

June 25 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES SAYS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ISSUED A DRAFT AGENDA AHEAD OF THEIR JUNE 25 TO 28 MEETING - SEC FILING.COHERUS BIOSCIENCES - FURTHER INTERACTIONS WITH CO REGARDING PEGFILGRASTIM BIOSIMILAR PRODUCT CANDIDATE CHS-1701 ISSUES ARE REQUIRED PRIOR TO CHMP OPINION.COHERUS BIOSCIENCES - ANTICIPATES INTERACTIONS WITH CHMP TO OCCUR PRIOR TO NEXT CHMP MEETING ON JULY 23 TO 26.  Full Article

Coherus Prices Public Offering Of Common Stock
Wednesday, 23 May 2018 

May 22 (Reuters) - Coherus BioSciences Inc ::COHERUS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.17 MILLION COMMON SHARES PRICED AT $14.50PER SHARE.  Full Article

Coherus Announces Proposed Public Offering Of Common Stock
Monday, 21 May 2018 

May 21 (Reuters) - Coherus BioSciences Inc ::COHERUS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.COHERUS BIOSCIENCES INC SAYS COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $75,000,000 OF SHARES OF ITS COMMON STOCK.  Full Article

Coherus Biosciences Says U.S. Court Grants Motion To Dismiss Patent Infringement Complaint
Monday, 26 Mar 2018 

March 26 (Reuters) - Coherus Biosciences Inc ::COHERUS BIOSCIENCES-U.S. COURT ADOPTED MAGISTRATE JUDGE BURKE'S REPORT & RECOMMENDATION TO GRANT MOTION OF CO TO DISMISS PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS PATENT INFRINGEMENT COMPLAINT AGAINST CO WAS FILED BY AMGEN INC & AMGEN MANUFACTURING LIMITED - SEC FILING.COHERUS BIOSCIENCES - PATENT INFRINGEMENT COMPLAINT WAS DISMISSED ON GROUNDS THAT COMPLAINT FAILED TO STATE CLAIM UPON WHICH RELIEF MAY BE GRANTED.  Full Article

Coherus Biosciences Says ‍Had Cash And Cash Equivalents Of About $126.9 Million
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Coherus Biosciences Inc ::COHERUS BIOSCIENCES SAYS ‍HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING​.  Full Article

Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Coherus Biosciences :COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM .COHERUS BIOSCIENCES SAYS ON DEC 7, JUDGE ISSUED UNDER SEAL REPORT AND RECOMMENDATION TO DISTRICT COURT IN RELATION TO PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS CO EXPECTS DISTRICT COURT TO DECIDE IN Q1 2018 WHETHER TO ADOPT MAGISTRATE JUDGE'S RECOMMENDATION - SEC FILING.COHERUS BIOSCIENCES SAYS ‍REPORT AND RECOMMENDATION ISSUED BY JUDGE WITH RESPECT TO LITIGATION BETWEEN AMGEN, AMGEN MANUFACTURING LTD, CO​.  Full Article

Coherus Biosciences Q3 loss per share $1.09
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences reports third quarter 2017 operating and financial results.Q3 loss per share $1.09.Q3 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.Coherus biosciences inc - ‍anticipate cash use in operations of about $35 - $40 million in Q4 of 2017​.  Full Article

UPDATE 2-FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

* Mylan shares up 5.2 pct, Amgen down 1.7 pct after market (Adds analyst comment, updates shares)